To this end, tocilizumab rather than steroids is used as concomitant medication to prevent CRS because this anti‐IL‐6R antibody—in contrast to steroids—does not interfere with the antitumor activity of CC‐1 (Kauer et al, 2020). This evidence concerns the gene IL6R and congenital rubella syndrome.